A 62-year-old woman with a 2-month history of jaundice and right upper quadrant pain undergoes ultrasound which shows a dilated common bile duct (12 mm) with multiple echogenic foci within it and a normal pancreatic head. The gallbladder is contracted with stones. Liver function tests show ALP 380 IU/L and direct bilirubin 7.5 mg/dL. What is the most appropriate next investigation to confirm the diagnosis and guide management?

Explanation

## Investigation of Choice for Obstructive Jaundice with Suspected Choledocholithiasis ### Clinical Context This patient presents with classic features of **choledocholithiasis**: - Jaundice with right upper quadrant pain - Dilated common bile duct (12 mm, normal <6 mm) - Multiple echogenic foci within the CBD (stones) - Contracted gallbladder with stones (source) - Elevated ALP and direct hyperbilirubinemia (biliary obstruction) - Normal pancreatic head (excludes pancreatic pathology) ### Why MRCP is the Investigation of Choice **Key Point:** MRCP is the gold standard non-invasive investigation for confirming choledocholithiasis and defining ductal anatomy before therapeutic intervention. ### Advantages of MRCP in Choledocholithiasis 1. **High sensitivity and specificity**: 85–95% for detecting CBD stones 2. **Ductal anatomy**: Clearly visualizes CBD, intrahepatic ducts, and pancreatic duct 3. **Non-invasive**: No risk of pancreatitis (unlike ERCP) 4. **Guides therapy**: Confirms stone presence and location, allowing planning of ERCP + sphincterotomy + stone extraction 5. **No radiation**: Magnetic resonance imaging—safe in pregnancy (if applicable) 6. **Simultaneous assessment**: Evaluates for strictures, dilated ducts, and excludes other pathology ### Comparison of Investigations for Suspected Choledocholithiasis | Investigation | Sensitivity for CBD Stones | Role | Timing | Risk | | --- | --- | --- | --- | --- | | **Ultrasound** | 50–60% | Initial screening | First-line | None | | **MRCP** | 85–95% | Confirmatory imaging | Before ERCP | None | | **EUS** | 95–98% | High sensitivity, therapeutic potential | When MRCP equivocal | Invasive, pancreatitis risk | | **ERCP** | 90–95% | Therapeutic (stone extraction) | After confirmation | High (pancreatitis 3–5%) | | **CECT** | 70–80% | Staging, excludes malignancy | Adjunct | Radiation | | **HIDA scan** | Low | Assesses biliary function | Not for stone detection | Radiation | ### Clinical Pearl **High-Yield:** The diagnostic algorithm for suspected choledocholithiasis is **Ultrasound → MRCP → ERCP**. Ultrasound detects gallstones and dilated ducts; MRCP confirms CBD stones and guides ERCP planning; ERCP is reserved for therapeutic intervention (sphincterotomy and stone extraction). ### Why Not the Other Options? **EUS**: While EUS has the highest sensitivity (95–98%) for detecting small CBD stones, it is **invasive** and carries a risk of pancreatitis. It is reserved for cases where MRCP is equivocal or unavailable, not as a first confirmatory test. **CECT**: CT has moderate sensitivity (70–80%) for CBD stones and is not the imaging of choice for choledocholithiasis. It is better suited for staging malignancy or assessing for complications. **HIDA scan**: This is a functional study assessing biliary excretion and is useful for acute cholecystitis (cystic duct patency) but has very low sensitivity for detecting stones within the CBD. ### Mnemonic: MRCP for Stones, ERCP for Extraction **MRCP** = **M**agnetic **R**esonance imaging for **C**holedocho**P**athy (diagnostic) **ERCP** = **E**ndoscopic **R**etrograde **C**holango**P**ancreatography (therapeutic) ### Expected Next Step Once MRCP confirms choledocholithiasis, the patient proceeds to **ERCP with endoscopic sphincterotomy and stone extraction** (or mechanical lithotripsy if stone is large).